amifampridine phosphate + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenic Syndromes, Congenital
Conditions
Myasthenic Syndromes, Congenital
Trial Timeline
Jan 1, 2016 → Oct 1, 2019
NCT ID
NCT02562066About amifampridine phosphate + Placebo
amifampridine phosphate + Placebo is a phase 3 stage product being developed by Catalyst Pharmaceuticals for Myasthenic Syndromes, Congenital. The current trial status is completed. This product is registered under clinical trial identifier NCT02562066. Target conditions include Myasthenic Syndromes, Congenital.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02562066 | Phase 3 | Completed |
| NCT01377922 | Phase 3 | Completed |
Competing Products
5 competing products in Myasthenic Syndromes, Congenital
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ARGX-119 | Argenx | Phase 1 | 30 |
| Amifampridine Phosphate | Catalyst Pharmaceuticals | Pre-clinical | 18 |
| Amifampridine Phosphate + Placebo | Catalyst Pharmaceuticals | Phase 3 | 72 |
| 3,4-Diaminopyridine | Catalyst Pharmaceuticals | Pre-clinical | 18 |
| Amifampridine Phosphate + Placebo Oral Tablet | Catalyst Pharmaceuticals | Phase 3 | 72 |